All recurrent respiratory papillomatosis articles
-
NewsPrecigen presents new long-term durability data for PAPZIMEOS, recently granted seven-year market exclusivity
Precigen, Inc. has announced updated long-term follow-up data from the pivotal study of PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP).